About the Company
MiMedx is an American biomedical company based in Marietta, Georgia, founded in 2008. Using tissues from birth such as the placenta, amniotic sac, and umbilical cord, MiMedx creates skin for skin grafts for medical use. During 2016-2019, the company went through a period of financial difficulty after allegations of mismanagement which resulted in Petit being terminated in 2018. With the arrival of Wright as CEO in May 2019, the company worked with auditors and regulators to resolve legal and financial issues created by the previous management (see ‘History’). Wright also began a cultural and financial turnaround, assembling a new senior management team by August 2019 to instill “transparency, truthfulness, and timeliness” in communications and business dealings. By August 2020, MiMedx had raised $150 million in concurrent private equity and debt financings; completed a required financial restatement; and filed its 2019 annual report and 2020 first-quarter report. MiMedx's application to relist its common stock on the NASDAQ was approved on October 30, 2020. The company had been delisted from the NASDAQ in November 2018 and had traded on OTC Pink until relisting. As of November 2020, MiMedx had supplied more than two million allografts for skin grafts to address persistent wounds such as diabetic foot ulcers that often result in amputation, burns, and other urgent health issues.
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & Apparatus
Employees
863
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on MIMEDX GROUP, INC.
MiMedx Group, Inc. Files Patent Infringement Lawsuit Against ... - Nasdaq
MiMedx Group, Inc. is actively protecting its intellectual property by filing a lawsuit against Surgenex, which may strengthen its market position and deter future infringements.
What To Expect From MiMedx Group Inc (MDXG) Q2 2025 Earnings
MiMedx Group Inc (NASDAQ:MDXG) is set to release its Q2 2025 earnings on July 30, 2025. The consensus estimate for Q2 2025 revenue is $90.62 million, and the earnings are expected to come in at $0 ...
Results: MiMedx Group, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
MiMedx Group, Inc. ( NASDAQ:MDXG ) defied analyst predictions to release its second-quarter results, which were ...
Why MiMedx Group Inc (MDXG) Shares Rebounded - Insider Monkey
What: Shares of MiMedx Group Inc (NASDAQ:MDXG), a manufacturer of patented regenerative biomaterial products, jumped as much as 22% today following yesterday's mammoth 36% decline after holding a ...
MiMedx Group, Inc. (NASDAQ:MDXG) insiders sold US$1.7m worth of stock ...
MiMedx Group Insider Transactions Over The Last Year In the last twelve months, the biggest single sale by an insider was when the Director, Timothy Wright, sold US$420k worth of shares at a price ...
MiMedx Group, Inc. (MDXG) Q2 2023 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG) Q2 2023 Earnings Conference Call August 1, 2023 5:00 PM ETCompany ParticipantsMatt Notarianni - Head, Investor Relations ...
MiMedx Group Inc. Reports Q3 2024 Financial Results
MiMedx Group Inc. ( (MDXG)) has realeased its Q3 earnings. Here is a breakdown of the information MiMedx Group Inc. presented to its investors. MiMedx Group Inc., a leader in placental tissue ...
MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ETCompany ParticipantsMatt Notarianni - Head, Investor ...
MiMedx Group (NASDAQ:MDXG) Shares Up 3.4% Following Insider Buying ...
MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. As a group, equities research analysts forecast that MiMedx Group, Inc. will post 0.3 earnings per share for the current ...
46,089 Shares in MiMedx Group, Inc. (NASDAQ:MDXG) Purchased by Proficio ...
MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $10.14. The stock has a fifty day moving average price of $8.36 and a 200-day moving average price of $7.88.
MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2022 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ: MDXG) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Good afternoon, and thank you for standing by.
Short-Seller Cohodes Sues MiMedx Over Defamation Claims
A short-seller who sought to expose accounting fraud at skin-graft maker MiMedx Group Inc. claimed in a defamation lawsuit that the company waged an illegal campaign to discredit him, including ...
Similar Companies
Loading the latest forecasts...